Showing results (111-120 of 2,810) with videos related to
Sort By:
Pageof 281
Expert Opinion on Drug Safety|November 2, 2021
Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profileG Vivanet, L Gervaso, A Laffi, et al.Expert Opinion on Drug Safety|October 1, 2021
Dermatologic adverse events associated with targeted therapies for melanomaLuigi Scarpato, Lucia Festino, Vito Vanella, et al.Expert Opinion on Drug Safety|March 1, 2022
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysisAnees Bahji, Carlos A Zarate, Gustavo H VazquezExpert Opinion on Drug Safety|November 6, 2023
Pneumatosis intestinalis associated with α-glucosidase inhibitors: a pharmacovigilance study of the FDA adverse event reporting system from 2004 to 2022Yiqian Chen, Yao Xiao, Guanghui Lian, et al.Expert Opinion on Drug Safety|November 14, 2023
Hospital registration of adverse drug reactions in electronic health records: importance and contribution to pharmacovigilanceRoba Alloush, Jette van Lint, Rob J van Marum, et al.Expert Opinion on Drug Safety|October 29, 2023
A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting systemCuicui Sun, Xiaoyan Yang, Linlin Tang, et al.Expert Opinion on Drug Safety|October 31, 2023
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myelomaShonali Midha, Monique A Hartley-Brown, Clifton C Mo, et al.Expert Opinion on Drug Safety|August 8, 2023
Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance studyMin Zhao, Shu Liu, Rui Xie, et al.Expert Opinion on Drug Safety|August 9, 2023
Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS)Fang-E Shi, Zhe Yu, Chengyue Sun, et al.Expert Opinion on Drug Safety|August 23, 2023
Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)Tingxi Wu, Yanfeng Shi, Bin Zhu, et al.Pageof 281